Larimar Therapeutics (LRMR) Cash from Operations (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Cash from Operations for 13 consecutive years, with -$19.4 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Cash from Operations fell 38.55% year-over-year to -$19.4 million; the trailing twelve-month figure through Jun 2025 stood at -$92.3 million (down 114.79% YoY), and the FY2025 full-year result was -$113.2 million, down 59.89% from the prior year.
• Cash from Operations rose to -$19.4 million in Q2 2025 per LRMR's latest filing, from -$26.5 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$5.9 million in Q3 2022 and bottomed at -$26.5 million in Q1 2025.
• Historically, Cash from Operations has averaged -$12.2 million across 5 years, with a median of -$9.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 51.82% in 2022, then tumbled 166.8% in 2024.
• Over 5 years, Cash from Operations stood at -$7.9 million in 2021, then advanced by 15.74% to -$6.7 million in 2022, then slumped by 40.65% to -$9.4 million in 2023, then sank by 132.9% to -$21.9 million in 2024, then increased by 11.32% to -$19.4 million in 2025.
• According to Business Quant data, Cash from Operations over the past three periods registered -$19.4 million, -$26.5 million, and -$21.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.